Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep 7:2020:4986365.
doi: 10.1155/2020/4986365. eCollection 2020.

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications

Carlo Messina  1 , Carlo Cattrini  2   3 , Davide Soldato  2   4 , Giacomo Vallome  2   4 , Orazio Caffo  1 , Elena Castro  3   5 , David Olmos  3   5 , Francesco Boccardo  2   4 , Elisa Zanardi  2   4
Affiliations
Review

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications

Carlo Messina et al. J Oncol. .

Abstract

Despite chemotherapy and novel androgen-receptor signalling inhibitors (ARSi) have been approved during the last decades, metastatic castration-resistant prostate cancer (mCRPC) remains a lethal disease with poor clinical outcomes. Several studies found that germline or acquired DNA damage repair (DDR) defects affect a high percentage of mCRPC patients. Among DDR defects, BRCA mutations show relevant clinical implications. BRCA mutations are associated with adverse clinical features in primary tumors and with poor outcomes in patients with mCRPC. In addition, BRCA mutations predict good response to poly-ADP ribose polymerase (PARP) inhibitors, such as olaparib, rucaparib, and niraparib. However, concerns still remain on the role of extensive mutational testing in prostate cancer patients, given the implications for patients and for their progeny. The present comprehensive review attempts to provide an overview of BRCA mutations in prostate cancer, focusing on their prognostic and predictive roles.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Mechanism of action of PARPi, platinum salts, and topoisomerase I inhibitors in the BRCA-mutated cell.
See this image and copyright information in PMC

References

    1. Fitzmaurice C., Allen C., Barber R. M. G., et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncology. 2017;3(4):524–548. doi: 10.1001/jamaoncol.2016.5688. - DOI - PMC - PubMed
    1. Siegel R. L., Miller K. D., Jemal A. Cancer statistics, 2018. CA: A Cancer Journal for Clinicians. 2018;68(1):7–30. doi: 10.3322/caac.21442. - DOI - PubMed
    1. James N. D., Sydes M. R., Clarke N. W., et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet. 2016;387(10024):1163–1177. doi: 10.1016/s0140-6736(15)01037-5. - DOI - PMC - PubMed
    1. Gillessen S., Omlin A., Attard G., et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Annals of Oncology. 2015;26(8):1589–1604. doi: 10.1093/annonc/mdv257. - DOI - PMC - PubMed
    1. Mucci L. A., Hjelmborg J. B., Harris J. R., et al. Familial risk and heritability of cancer among twins in Nordic Countries. JAMA. 2016;315(1):68–76. doi: 10.1001/jama.2015.17703. - DOI - PMC - PubMed